首页> The Lancet. Infectious diseases> Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.

导出 OA

翻译打印收藏纠错

第一作者： Pedro M,Folegatti

第一单位： The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

作者： Pedro M,Folegatti ^[1] ; Mustapha,Bittaye ^[1] ; Amy,Flaxman ^[1] ; Fernando Ramos,Lopez ^[1] ; Duncan,Bellamy ^[1] ; Alexandra,Kupke ^[2] ; Catherine,Mair ^[1] ; Rebecca,Makinson ^[1] ; Jonathan,Sheridan ^[1] ; Cornelius,Rohde ^[2] ; Sandro,Halwe ^[2] ; Yuji,Jeong ^[3] ; Young-Shin,Park ^[3] ; Jae-Ouk,Kim ^[3] ; Manki,Song ^[3] ; Amy,Boyd ^[1] ; Nguyen,Tran ^[1] ; Daniel,Silman ^[1] ; Ian,Poulton ^[1] ; Mehreen,Datoo ^[1] ; Julia,Marshall ^[1] ; Yrene,Themistocleous ^[1] ; Alison,Lawrie ^[1] ; Rachel,Roberts ^[1] ; Eleanor,Berrie ^[1] ; Stephan,Becker ^[2] ; Teresa,Lambe ^[1] ; Adrian,Hill ^[1] ; Katie,Ewer ^[1] ; Sarah,Gilbert ^[4]

作者单位： The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. ^[1] Institute of Virology, Philipps University of Marburg, Marburg, Germany; German Center for Infection Research, Thematic Translational Unit Emerging Infections, Marburg, Germany. ^[2] International Vaccine Institute, Science Unit, Seoul, South Korea. ^[3] The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address: sarah.gilbert@ndm.ox.ac.uk. ^[4]